Treptora 25 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Eltrombopag olamine |
| Company | Genvio pharma ltd |
| Also available as |
Indications
- Treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia
- Treatment of thrombocytopenia in patients with hepatitis C infection
- Treatment of severe aplastic anemia
Pharmacology
Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist. Eltrombopag interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells finally leading to increased platelet production.
Dosage & Administration
- Route of administration: Oral
- Administration with or without a meal low in calcium
- Dosage for different conditions such as persistent or chronic immune thrombocytopenia, chronic hepatitis C associated thrombocytopenia, and severe aplastic anemia
Interaction
- Drug interaction with medication: Take eltrombopag at least 2 hours before or 4 hours after any medications containing polyvalent cations
- Drug interaction with food and others: Take eltrombopag at least 2 hours before or 4 hours after any calcium rich foods
Contraindications
Contraindicated in patients with known hypersensitivity to eltrombopag or any components of this product
Side Effects
- Anemia
- Nausea
- Pyrexia
- ALT increased
- Cough
- Fatigue
- Headache
- Diarrhea
Pregnancy & Lactation
No sufficient data is available to assess any drug-associated risks for major birth defects, miscarriage or adverse maternal or fetal outcomes. Breastfeeding is not recommended during treatment.
Precautions & Warnings
Increased risk of hepatic decompensation in combination with interferon and ribavirin, increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia, portal vein thrombosis reported in patients with chronic liver disease
Use in Special Populations
Safety and efficacy in pediatric patients below the age of 1 year with ITP have not been established. Safety and efficacy in pediatric patients with thrombocytopenia associated with chronic hepatitis C and refractory severe aplastic anemia have not been established.
Overdose Effects
Platelet counts may increase excessively and result in thrombotic or thromboembolic complications. Consider oral administration of a metal cation containing preparation to chelate eltrombopag in case of an overdose.
Therapeutic Class
Haemostatic drugs
Storage Conditions
Store in a cool (below 25°C) and dry place protected from light. Keep away from the reach of children